IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
14/26/14	€0.1230	-40.00%
11/26/11	€0.2050	-5.96%
10/26/10	€0.2180	-0.46%
09/26/09	€0.2190	-3.10%
08/26/08	€0.2260	+27.32%

Delayed Quote Börse Stuttgart

More quotes

Delayed Börse Stuttgart 11:18:01 14/09/2026 pm IST			5-day change	1st Jan Change
0.1230 ^EUR	-40.00%		-30.70%	+53.75%

11/09	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
11/09	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

Market Cap	9L 10.16L 8L 8L 14.14L 9.74Cr 14.24L 99.24L 38.24L 4.94Cr 38.17L 37.33L 16Cr	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-22.28L -25.72L -21.03L -19.08L -35.79L -25Cr -36.05L -2.51Cr -96.78L -13Cr -96.59L -94.46L -40Cr	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

11/09	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
11/09	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
16/06	IntegraGen Enters Receivership Proceedings
28/05	IntegraGen to file for court-ordered receivership
24/04	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
23/04	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/25/02	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/25/02	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
29/25/29	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/25/15	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
18/24/18	IntegraGen: losses reduced, share price soars
30/24/30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI

IntegraGen Share Price Börse Stuttgart

Stocks

7N8

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news: IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

02/25/02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/25/02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
29/25/29	IntegraGen: 2024 Annual Results	BU
16/25/16	IntegraGen : Inside Information / Information on annual revenues	PU
15/25/15	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

12:32pm	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
11:07am	La love story du marché avec l'IA connaît quelques ratés
10:40am	Deux offres de reprise déposées pour IntegraGen
12/09	IntegraGen annonce le dépôt de deux offres de reprise dans le cadre de son redressement judiciaire
16/06	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime

1 day	-40.00%
1 week	-30.70%
Current month	-29.91%
1 month	-32.23%
3 months	-38.35%
6 months	-28.70%
Current year	+53.75%

1 week	0.12	0.23
1 month	0.12	0.23
Current year	0.1	0.33
1 year	0.07	0.33
3 years	0.07	1.32
5 years	0.07	1.46
10 years	0.07	1.46

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	09/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	01/01/2023
Berengere Genin COO	Chief Operating Officer	-	01/01/2024

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	22/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	01/01/2021
François Blondel BRD	Director/Board Member	63	31/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	-40.00%	-30.70%	-	-	15.27L
IOVANCE BIOTHERAPEUTICS, INC.	+7.73%	+6.38%	+307.71%	+99.25%	389.56Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+1.88%	+1.31%	+88.53%	+297.10%	386.22Cr
VERACYTE, INC.	+0.46%	-3.16%	+28.99%	+63.07%	328.56Cr
CAREDX, INC.	+3.96%	+3.70%	+272.11%	+536.22%	260.02Cr
BGI GENOMICS CO., LTD.	+2.37%	-0.38%	-33.13%	-30.48%	205.23Cr
FREENOME, INC.	+1.60%	-11.89%	+36.21%	-	154.4Cr
SEEGENE, INC.	+1.27%	+0.16%	+22.88%	+42.00%	107.24Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+3.14%	-6.33%	+147.61%	-34.80%	97Cr
CURIOX BIOSYSTEMS CO., LTD	-0.83%	-0.10%	-6.48%	+78.95%	62Cr
Average	-1.83%	-3.48%	+96.05%	+131.41%	221.12Cr
Weighted average by Cap.	+3.06%	-2.85%	+125.39%	+170.66%

	2019	2020
Net sales	82.8L 95.56L 78.14L 70.89L 1.33Cr 92Cr 1.34Cr 9.33Cr 3.6Cr 46Cr 3.59Cr 3.51Cr 147.71Cr	90L 1.04Cr 84.93L 77.05L 1.45Cr 100Cr 1.46Cr 10Cr 3.91Cr 51Cr 3.9Cr 3.82Cr 160.56Cr
Net income	-3L -3L -3L -2L -5L -3.15Cr -5L -32.1L -12.37L -1.6Cr -12.35L -12.07L -5.08Cr	-4L -4L -4L -3L -6L -4.15Cr -6L -42.26L -16.29L -2.1Cr -16.25L -15.9L -6.69Cr
Net Debt	-25.19L -29.07L -23.77L -21.56L -40.45L -28Cr -40.74L -2.84Cr -1.09Cr -14Cr -1.09Cr -1.07Cr -45Cr	-31.09L -35.88L -29.34L -26.62L -49.93L -34Cr -50.29L -3.5Cr -1.35Cr -17Cr -1.35Cr -1.32Cr -55Cr